SBIO

ALPS Medical Breakthroughs ETF
*Unless otherwise stated, data provided by FactSet.

SBIO Fund Description

SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

SBIO Factset Analytics Insight

SBIO invests in a concentrated portfolio of biotech companies with drugs in Phase II and Phase III of U.S. Food and Drug Administration (FDA) clinical trials, and limits itself to US-listed firms with market caps between USD 200 million and USD 5 billion. SBIO also screens for sustainability, meaning constituent firms have enough cash on hand to last two years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. The Underlying Index undergoes semi-annual reconstitution and quarterly rebalance subject to certain caps. The largest stock is capped at 4.5%, and the excess weight is redistributed proportionately over the remainder of the Underlying Index. Prior to July 9, 2019 the fund’s index was Poliwogg Medical Breakthroughs Index, which has the same strategies.

SBIO MSCI ESG Analytics Insight

ALPS Medical Breakthroughs ETF has an MSCI ESG Fund Rating of BB based on a score of 3.72 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ALPS Medical Breakthroughs ETF ranks in the 8th percentile within its peer group and in the 21st percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

SBIO MSCI FaCS and Factor Box

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.

PERFORMANCE [as of 09/15/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
SBIO 4.87% -8.19% -10.50% 12.43% 8.21% 13.77% --
SBIO (NAV) 6.32% -5.28% -9.40% 13.35% 8.68% 13.48% --
Thomson Reuters US Biotechnology & Medical Research -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

SBIO Summary Data

SS&C
ALPS
12/31/14
Open-Ended Fund
0.50%
$208.66M
$795.11K
0.25%

SBIO Portfolio Data

$2.38B
-11.10
4.05
0.03%
N/A
126

SBIO Index Data

S-Network Medical Breakthroughs Index
Market Cap
Fundamental
Thomson Reuters US Biotechnology & Medical Research

SBIO Portfolio Management

0.50%
--
--
--

SBIO Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

SBIO Fund Structure

Open-Ended Fund
No
Yes
-- / --
N/A
N/A
Low
Daily

SBIO Factset Analytics Block Liquidity

As of 09/16/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of SBIO. SBIO is rated a 5 out of 5.

SBIO Tradability

17,613
$795.11K
15,437
$678.39K
0.25%
$0.11
-0.06%
0.42% / -0.28%
None
93.00%
50,000
0.31
0.02%
0.36%
529
$46.44
5

SBIO Sector/Industry Breakdown


SBIO
Segment Benchmark
47.82%
42.17%
31.49%
46.79%
6.76%
--
6.01%
0.23%
2.16%
5.72%

SBIO Top 10 Holdings[View All]

3.09%
Alkermes Plc 2.96%
26.36%

SBIO Countries


SBIO
Segment Benchmark
92.62%
100.00%
3.67%
--
2.00%
--
1.46%
--
0.17%
--
0.08%
--

SBIO Regions


SBIO
Segment Benchmark
92.62%
100.00%
3.92%
--
3.47%
--

SBIO Economic Development


SBIO
Segment Benchmark
96.33%
100.00%
3.67%
--

SBIO Performance Statistics

0.80
1.18
1.27
1.18
0.91%
Thomson Reuters US Biotechnology & Medical Research

SBIO MSCI ESG Ratings

3.72 / 10
20.68
8.22
--
8.90%
26.66

SBIO Benchmark Comparison Holdings

126
261
89
11.02%

SBIO Benchmark Comparison Summary


SBIO
Segment Benchmark
126
261
$2.38B
$43.30B
-11.10
-58.34
4.05
6.44
0.05%
0.39%
Low
High

SBIO Benchmark Comparison Market Cap Size


SBIO
Segment Benchmark
0.00%
58.24%
36.75%
25.73%
52.65%
13.19%
10.59%
2.85%